Background and Purpose: Cerebral arterioles are relatively unresponsive to norepinephrine. We tested the hypothesis that release of endothelium-derived relaxing factor is stimulated by norepinephrine and attenuates adrenergic constriction of pial arterioles.
C erebral arteries are less responsive than other blood vessels to adrenergic stimuli. 1 The diminished responsiveness of cerebral vessels to norepinephrine does not appear to be caused by increases in neuronal or extraneuronal uptake of the agonist. 2 Mechanisms that account for the small magnitude of responses of cerebral vessels to adrenergic stimuli are unresolved.
In some extracranial vessels, norepinephrine can cause release of endothelium-derived relaxing factor (EDRF), which attenuates vasoconstrictor responses. 3 In microcirculation of skeletal muscle and in isolated coronary arteries, 4 " 6 vasoconstrictor responses to norepinephrine are augmented by removal of endothelium or by specific inhibitors of nitric oxide (EDRF) synthase. In cerebral arteries in vitro, responses to norepinephrine are augmented by removal of endothelium, 7 which suggests that norepinephrine may release EDRF in cerebral as well as other blood vessels.
The purpose of this study was to test the hypothesis that norepinephrine-mediated release of EDRF contributes to the small magnitude of response to norepinephrine in cerebral arterioles in vivo. We used N Gnitro-L-arginine to inhibit synthesis of EDRF and to determine whether the contractile response of cerebral vessels to norepinephrine was augmented.
Materials and Methods
Experiments were performed on seven New Zealand White rabbits (2-3 kg) of both sexes anesthetized with 30 mg/kg i.v. pentobarbital. A tracheostomy was performed, and the animals were mechanically ventilated with room air and supplemental oxygen. Skeletal muscle paralysis was produced with 5 mg/kg i.v. gallamine triethiodide. Because the animals were paralyzed, we evaluated them approximately every 20 minutes for adequacy of anesthesia. When pressure to a paw evoked a change in blood pressure or heart rate, additional pentobarbital was administered intravenously at a rate of approximately 20-40 mg/kg per hour.
Catheters were placed in both femoral arteries and advanced to the aorta to measure systemic pressure and obtain arterial blood samples. A femoral vein was cannulated for infusion of drugs. Arterial blood gases were monitored frequently and maintained within normal limits throughout the experiment: Pco 2 , 39.8±1.8 (mean±SE) mm Hg; Po 2 , 115.7±6.3 mm Hg; and pH, 7.42±0.02. Core temperature was measured continuously and maintained at 37°C with a heating pad.
A craniotomy was performed over the right or left parietal cortex as described previously. 8 The cranial window was suffused with artificial cerebrospinal fluid (CSF) bubbled continuously with 95% nitrogen and 5% carbon dioxide. The ionic composition of CSF (raM) was as follows: 132 NaCl, 2.95 KC1, 1.71 CaCl 2 , 0.65 MgCl 2 , 24.6 NaHCO 3 , and 3.69 D-glucose. The temperature of the suffusate was maintained at a constant 38°C. Gas partial pressures, pH, and temperature of the CSF suffusate were constant throughout the experiment (Pco 2 , 44.5±1.7 mmHg; Po 2 , 52.2±3.3 mmHg; pH, 7.30±0.01; and temperature, 37.5±0.3°C).
Diameters of pial arterioles were measured using a microscope equipped with a television camera coupled with a monitor and an image-shearing device (Model 907, Instrumentation for Physiology and Medicine, San Diego, Calif.).
Experimental Protocol
Cerebral vessels were superfused with artificial CSF for 30 minutes before testing responses of arterioles to the agonists. We examined responses of cerebral arterioles to norepinephrine (10~7 and 10~6 M), arginine vasopressin (10~9 to 10" 8 M), acetylcholine (10" 6 and 10" 5 M), AT G -nitro-L-arginine (10~4 M), and L-arginine (10~3 M). All drugs were obtained from Sigma Chemical Co., St. Louis, Mo., except arginine vasopressin (Peninsula Laboratories, Inc., Belmont, Calif.) and norepinephrine bitartrate (Winthrop Pharmaceuticals, New York).
Drugs were mixed in artificial CSF, then superfused over the cerebral microcirculation. In each rabbit, we studied responses of a single pial arteriole to agonists. Diameter of cerebral arterioles was measured immediately before application of agonists and at steady state (after 3 minutes of continuous application). Nitro-Larginine and L-arginine were superfused for at least 5 minutes before and during the addition of agonists to the cranial window. Allowing for time for measurements, vessels were exposed to nitro-L-arginine for 10 minutes before the first measurements during superfusion of agonists. In pilot experiments, vessel diameter reached a steady state within 3 minutes of administration of agonists. Neither longer nor shorter exposure times resulted in further changes in vessel diameter.
Pial arteriolar response to acetylcholine suffusion (10~6 or 10" 5 M) was assessed at the beginning of each experiment to confirm that endothelium-dependent responsiveness was present. Pilot experiments established an effective inhibitor concentration of nitro-L-arginine to acetylcholine-induced vasodilation. The effect of nitro-L-arginine and L-arginine on baseline diameter was assessed in each animal.
The effect of nitro-L-arginine on responsiveness to the endothelium-dependent vasodilator acetylcholine as well as the vasoconstrictors norepinephrine and arginine vasopressin was determined in the following manner. Baseline responses to agonists were measured, allowing time for return to control diameter between each drug application. The series of drug applications was repeated during simultaneous administration of 10~4 M nitro-L-arginine. The order of application of agonists was usually randomized. Administration of agonists was repeated during simultaneous administration of nitro-L-arginine and 10~3 M L-arginine. L-Arginine, the substrate for synthesis of EDRF, was administered to prevent the inhibitor effects of nitro-L-arginine. This dosage of L-arginine was established in pilot experiments to effectively prevent the inhibitory effect of 10" 4 nitro-L-arginine on acetylcholine-mediated vasodilatation.
Variables were analyzed using repeated measures analysis of variance. Individual comparisons were performed by defining mean contrasts, which were tested with a t test. A value of p<0.05 was considered significant. All values are presented as mean±SE.
Results
Under control conditions, diameter of pial arterioles was 60 ±7 /Am. Superfusion of nitro-L-arginine (10~4 M) did not alter diameter of pial arterioles (2±3%). Superfusion of L-arginine (10~3 M) also did not alter arteriolar diameter (2±2%).
Acetylcholine produced significant dilatation of pial arterioles (Figure 1 ). Simultaneous administration of nitro-L-arginine inhibited acetylcholine-mediated vasodilatation. The vasodilator response to acetylcholine was partially restored with concomitant superfusion of L-arginine (10~3 M).
Under baseline conditions, norepinephrine did not produce vasoconstriction (Figure 2 ). In the presence of nitro-L-arginine, norepinephrine produced significant, concentration-related constriction of pial arterioles. L-Arginine prevented vasoconstrictor responses to norepinephrine in the presence of nitro-L-arginine.
Topical application of arginine vasopressin produced constriction of cerebral arterioles (Figure 3) . In contrast to norepinephrine, simultaneous administration of 10~4 M nitro-L-arginine did not potentiate vasoconstrictor response to arginine vasopressin. Concomitant administration of L-arginine and nitro-L-arginine did not alter the response to arginine vasopressin.
Discussion
The major finding in this study is that norepinephrine, which had little effect on cerebral vessels under baseline conditions, produced constriction of cerebral arterioles after inhibition of synthesis of EDRF. Thus, norepi- nephrine releases EDRF from cerebral arterioles, which then prevents vasoconstrictor responses to norepinephrine. This mechanism may account, in part, for the finding that cerebral vessels are relatively unresponsive to noradrenergic stimuli. In cerebral vessels the chemical nature of EDRF is incompletely defined. The finding that the L-arginine analogue (nitro-L-arginine) inhibits responses to acetylcholine and potentiates responses to norepinephrine suggests that the EDRF that is released by acetylcholine and norepinephrine is nitric oxide or a related compound.
The concentration of 10~4 M nitro-L-arginine was chosen for these experiments because our previous experiments suggest that a lower concentration of nitro-L-arginine (10~5 M) produces less effective inhibition of EDRF-mediated vasodilatation in the rabbit than in the rat. Responses to norepinephrine with lower concentrations of nitro-L-arginine were not tested in this experiment.
Several lines of evidence suggest that this concentration of nitro-L-arginine inhibited synthesis of EDRF selectively. First, nitro-L-arginine inhibited acetylcholine-mediated vasodilatation. Second, the effect of nitro-L-arginine on responses to acetylcholine and norepinephrine was inhibited by L-arginine. Third, the response to arginine vasopressin, which was used here as an internal control, is not potentiated by nitro-Larginine at this concentration. Studies of cerebral arteries 7 and other blood vessels 4 " 6 in vitro indicate that endothelial denudation or inhibitors of synthesis of EDRF potentiate vasoconstrictor responses to norepinephrine. This hypothesis, that norepinephrine releases EDRF from cerebral vessels, has not been tested previously in vivo.
Contraction of isolated human coronary arteries and constrictor responses of the microcirculation of skeletal muscle to norepinephrine are potentiated by an inhibitor of synthesis of EDRF. 5 ' 6 In these blood vessels, release of EDRF attenuates, but does not prevent, vasoconstrictor responses to norepinephrine. Thus, our findings suggest that modulation of responses to norepinephrine by EDRF may be especially important in cerebral vessels.
Blood-borne norepinephrine has little effect on the cerebral circulation, 1 presumably because the endothelial blood-brain barrier prevents access of norepinephrine to smooth muscle in cerebral vessels. In this study, norepinephrine was applied topically to circumvent the blood-brain barrier.
A recent study 9 reported that norepinephrine dilates pial arterioles at low concentrations but produces vasoconstriction at high concentrations in cats. The authors observed that constrictor responses to norepinephrine were preserved after injury to arteriolar endothelium produced by air embolism. Their conclusion, that endothelium has little modulatory effect on constrictor responses to norepinephrine, may not be correct, however. Arteriolar diameter was increased 27% by air embolism, and the influence of this large change in vessel diameter on vascular reactivity was not examined. It is possible that dilator responses to low concentrations of norepinephrine were reduced by the change in baseline diameter.
Recently Moskowitz and colleagues 10 reported that constrictor responses of pial arteries to norepinephrine are augmented after chronic trigeminal ganglionectomy in cats. They postulated that norepinephrine facilitates release of a peptidergic vasodilator neurotransmitter, such as substance P, from trigeminal fibers. We cannot exclude the possibility that, in the present experiments, norepinephrine stimulated release of substance P, an endothelium-dependent vasodilator, which attenuated direct constrictor effects of norepinephrine. Under these conditions, nitro-L-arginine would be expected to augment vasoconstriction in response to norepinephrine by inhibition of EDRF produced in response to release of substance P.
The small magnitude of response to norepinephrine presumably contributes to the finding that stimulation of sympathetic nerves has little effect on the cerebral circulation under normal conditions. 811 Sympathetic stimulation, however, has important vasoconstrictor effects in cats, dogs, and monkeys during acute hypertension, 1213 which indicates that cerebral vessels are not intrinsically unresponsive to noradrenergic stimuli.
Several factors may account for augmentation of cerebral vasoconstrictor responses to sympathetic.stimulation during acute hypertension. We speculate that the findings in this study in rabbits may have implications for understanding altered responses during acute hypertension in other species. 13 Superoxide anion inactivates EDRF in cerebral blood vessels 14 and in other vessels. 15 In the present study, we observed that norepinephrine releases EDRF, which attenuates vasoconstrictor responses to norepinephrine. We speculate that generation of superoxide anion by acute hypertension 14 may inactivate EDRF that is released by norepinephrine and thereby augment cerebral vasoconstrictor responses to sympathetic stimulation.
In summary, we suggest that release of EDRF may prevent cerebral vasoconstrictor responses to norepinephrine under normal conditions. We speculate that inactivation of EDRF by superoxide anion during acute hypertension may unmask cerebral vasoconstrictor responses to adrenergic stimuli.
